FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bernard Escudier

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Killer Cells, Natural

Co-author Network

Publications

TOP 3
Aurore Blesius; Christine Chevreau; Stéphane Oudard; Alain Ravaud; Frédéric Rolland; Benoit Beuselinck; Bernard Escudier
Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial.
Robert J Motzer; Sylvie Negrier; Stéphane Oudard; Connie Chen; Bernard Escudier; Martin E Gore; Subramanian Hariharan; Thomas E Hutson; Sinil Kim; M Dror Michaelson; Brad Rosbrook; Jamal Tarazi; Piotr Tomczak; Brian I Rini
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Bernard Escudier; Laurence Albiges; Guru Sonpavde
Optimal management of metastatic renal cell carcinoma: current status.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bernard Escudier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Aurore Blesius; Christine Chevreau; Stéphane Oudard; Alain Ravaud; Frédéric Rolland; Benoit Beuselinck; Bernard Escudier
Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial.
Clinical genitourinary cancer 2013;11(2):128-33.
2013: Robert J Motzer; Sylvie Negrier; Stéphane Oudard; Connie Chen; Bernard Escudier; Martin E Gore; Subramanian Hariharan; Thomas E Hutson; Sinil Kim; M Dror Michaelson; Brad Rosbrook; Jamal Tarazi; Piotr Tomczak; Brian I Rini
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
The lancet oncology 2013;14(6):552-62.
2013: Bernard Escudier; Laurence Albiges; Guru Sonpavde
Optimal management of metastatic renal cell carcinoma: current status.
Drugs 2013;73(5):427-38.
2012: Brian Rini; Wojciech Rogowski; Yu-Nien Sun; Cezary Szczylik; Nizar M Tannir; Piotr Tomczak; Michael B Bass; Andrzej Deptala; Luc Y Dirix; Mayer Fishman; Piotr Koralewski; Karolyn Kracht; Markus Puhlmann; Rodryg Ramlau; Alain Ravaud; Bernard Escudier
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Cancer 2012;118(24):6152-61.
2012: Roberto Iacovelli; Emilie Lanoy; Laurence Albiges; Bernard Escudier
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
BJU international 2012;110(11):1747-53.
2012: Sujata Patil; Sylvie Negrier; Michael Atkins; Ronald Bukowski; Tim Eisen; Paul Elson; Bernard Escudier; Judith Manola; Robert J Motzer
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.
The Journal of urology 2012;188(6):2095-100.
2012: Bernard Escudier; V Kataja; V Khoo; P Mulders; J J Patard; C Porta; F Algaba; T Eisen
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 7():vii65-71.
2012: Bernard Escudier
Emerging immunotherapies for renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 8():viii35-40.
2012: Bernard Escudier; Camillo Porta; Cezary Szczylik; Martin Gore
Treatment selection in metastatic renal cell carcinoma: expert consensus.
Nature reviews. Clinical oncology 2012;9(6):327-37.
2012: Bernard Escudier; Alex Franklin; Martin Gore; Per Hartvig Honoré; Börje Ljungberg; Peter Mulders; Susanne Osanto; Camillo Porta; Alain Ravaud; Jeanne van Steijn; John Wagstaff; Zeba Aziz; Joaquim Bellmunt; Axel Bex; Sergio Bracarda; Hideyuki Akaza
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.
Cancer treatment reviews 2012;38(2):127-32.
2012: Bernard Escudier
Metastatic RCC: moving towards a chronic disease.
Oncology (Williston Park, N.Y.) 2012;26(3):304, 306.
2012: Laurence Albiges; Armelle Caty; Pierre-Yves Dietrich; Brigitte Duclos; Lionel Geoffrois; Gwenaëlle Gravis; Aline Guillot; Florence Joly; Frédéric Kohser; Brigitte Laguerre; Eric Legouffe; Sylvie Negrier; Stéphane Oudard; Frédéric Rolland; Christine A Theodore; Bernard Escudier
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):482-7.
2012: Laurence Albiges; Vincent Molinie; Bernard Escudier
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
The oncologist 2012;17(8):1051-62.
2012: Salem Chouaib; Sophie Couve; Bernard Escudier; Meriem Hasmim; Yosra Messai; Muhammad Zaeem Noman
Hypoxia promotes tumor growth in linking angiogenesis to immune escape.
Frontiers in immunology 2012;3():21.
2011: Jean-Jacques Patard; Geraldine Pignot; Brian Rini; Jan Roigas; Cora Sternberg; Axel Bex; Ronald Bukowski; Toni Choueiri; Tim Eisen; Bernard Escudier; Ziya Kirkali; Robert Motzer; Peter Mulders; Joaquim Bellmunt
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
European urology 2011;60(4):684-90.
2011: T Bessede; S Droupy; B Albouy; Karim Fizazi; Marine Gross-Goupil; S Leborgne; Christophe Massard; J-J Patard; Bernard Escudier
Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(10):2320-4.
2011: Laurence Albiges; Brian Rini; Mohamed Salem; Bernard Escudier
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Hematology/oncology clinics of North America 2011;25(4):813-33.
2011: Sylvie Négrier; David Pérol; Frédéric Rolland; Emmanuel Sevin; Jacques-Olivier Bay; Ellen Blanc; Christine Chevreau; Rémi Delva; Céline Ferlay; Lionel Geoffrois; Gwenaelle Gravis; Brigitte Laguerre; Eric Legouffe; Bernard Escudier
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
The lancet oncology 2011;12(7):673-80.
2011: Bernard Escudier; Laurence Albiges
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.
Drugs 2011;71(9):1179-91.
2011: Bernard Escudier
Progression-free survival as a surrogate marker of overall survival: Is it the good question?
Cancer 2011;117(12):2586-7.
2011: A Perier; Sebastian Wittnebel; M Allard; Bruno Azzarone; Bernard Escudier; G Fregni; S Gad; Nadine Gervois; A Caignard
Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Oncogene 2011;30(23):2622-32.
2011: Bernard Escudier
Sorafenib for the management of advanced renal cell carcinoma.
Expert review of anticancer therapy 2011;11(6):825-36.
2011: Bernard Escudier
Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(5):995-6.
2011: Pramod Rao; Bernard Escudier; Thierry de Baere
Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis.
Cardiovascular and interventional radiology 2011;34(2):424-30.
2011: Françoise Farace; Marine Gross-Goupil; E Tournay; M Taylor; N Vimond; N Jacques; F Billiot; A Mauguen; C Hill; Bernard Escudier
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
British journal of cancer 2011;104(7):1144-50.
2011: Bernard Escudier; Martin Gore
Axitinib for the management of metastatic renal cell carcinoma.
Drugs in R&D 2011;11(2):113-26.
2011: Gabriel G Malouf; Philippe Camparo; Vincent Molinié; Guillaume Dedet; Stéphane Oudard; Gudrun Schleiermacher; Christine Theodore; Janice Dutcher; Bertrand Billemont; Emmanuelle Bompas; Aline Guillot; Liliane Boccon-Gibod; Jérôme Couturier; Bernard Escudier
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.
The Journal of urology 2011;185(1):24-9.
2010: Christophe Massard; Karim Fizazi; Marine Gross-Goupil; Bernard Escudier
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus.
Investigational new drugs 2010;28(6):879-81.
2010: Bernard Escudier; L Albiges; A Blesius; Yohann Loriot; Christophe Massard; Karim Fizazi
How to select targeted therapy in renal cell cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 7():vii59-62.
2010: Carol Peña; Chetan Lathia; Minghua Shan; Bernard Escudier; Ronald M Bukowski
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4853-63.
2010: Judith Michels; Nathalie Lassau; Marine Gross-Goupil; Christophe Massard; Arnaud Mejean; Bernard Escudier
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Investigational new drugs 2010;28(5):690-3.
2010: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Cancer 2010;116(18):4256-65.
2010: S Rajpar; Christophe Massard; Agnès Laplanche; E Tournay; Marine Gross-Goupil; Yohann Loriot; Mario Di Palma; A Bossi; Bernard Escudier; A Chauchereau; Karim Fizazi
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(9):1864-9.
2010: G G Malouf; P Camparo; Stéphane Oudard; G Schleiermacher; Christine Theodore; A Rustine; J Dutcher; B Billemont; Olivier Rixe; Emmanuelle Bompas; A Guillot; L Boccon-Gibod; J Couturier; V Molinié; Bernard Escudier
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(9):1834-8.
2010: Sylvie Negrier; E Jäger; C Porta; D McDermott; M Moore; J Bellmunt; S Anderson; F Cihon; J Lewis; Bernard Escudier; R Bukowski
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Medical oncology (Northwood, London, England) 2010;27(3):899-906.
2010: Dorothy A White; Philippe Camus; Masahiro Endo; Bernard Escudier; Emiliano Calvo; Hideyuki Akaza; Hirotsugu Uemura; Euloge Kpamegan; Andrea Kay; Matthew Robson; Alain Ravaud; Robert J Motzer
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
American journal of respiratory and critical care medicine 2010;182(3):396-403.
2010: Christophe Massard; Anne Plantade; Marine Gross-Goupil; Yohann Loriot; Benjamin Besse; Bruno Raynard; F Blot; Sami Antoun; G Nitenberg; Bernard Escudier; Karim Fizazi
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(8):1585-8.
2010: Sami Antoun; Vickie E Baracos; L Birdsell; Bernard Escudier; M B Sawyer
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(8):1594-8.
2010: Yohann Loriot; Christophe Massard; Marine Gross-Goupil; Mario Di Palma; Bernard Escudier; Alberto Bossi; Anne Chauchereau; Karim Fizazi
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
European journal of cancer (Oxford, England : 1990) 2010;46(10):1770-2.
2010: Bernard Escudier; V Kataja
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 5():v137-9.
2010: Bernard Escudier; Joaquim Bellmunt; Sylvie Négrier; Emilio Bajetta; Bohuslav Melichar; Sergio Bracarda; Alain Ravaud; Sophie Golding; sangeeta jethwa; Vesna Sneller
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(13):2144-50.
2010: Christophe Massard; J Zonierek; Marine Gross-Goupil; Karim Fizazi; C Szczylik; Bernard Escudier
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(5):1027-31.
2010: Bernard Escudier
Sunitinib for the management of advanced renal cell carcinoma.
Expert review of anticancer therapy 2010;10(3):305-17.
2010: Bernard Escudier
Chemo-immunotherapy in RCC: the end of a story.
Lancet 2010;375(9715):613-4.
2010: Sami Antoun; Laura Birdsell; Michael B Sawyer; Peter Venner; Bernard Escudier; Vickie E Baracos
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(6):1054-60.
2010: Nathalie Lassau; Serge Koscielny; Laurence Albiges; Linda Chami; Baya Benatsou; Mohamed Chebil; Alain Roche; Bernard Escudier
Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1216-25.
2010: Marine Gross-Goupil; Bernard Escudier
[Targeted therapies: sequential and combined treatments].
Bulletin du cancer 2010;97():65-71.
2010: B Albouy; Marine Gross-Goupil; Bernard Escudier; Christophe Massard
[Renal cell carcinoma management and therapies in 2010].
Bulletin du cancer 2010;97():17-28.
2010: L Albiges; Yohann Loriot; Marine Gross-Goupil; Thibault de La Motte Rouge; A Blesius; Bernard Escudier; Christophe Massard; Karim Fizazi
[New drugs in metastatic castration-resistant prostate cancer].
Bulletin du cancer 2010;97(1):149-59.
2009: Bernard Escudier; P Paparel; Y Neuzillet; J-A Long; N Rioux-Leclercq; J-M Correas; H Lang; L Poissonnier; H Baumert; A Mejean; J-J Patard
[Treatment of metastatic kidney cancer in elderly subjects].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2009;19 Suppl 3():S129-32.
2009: Bernard Escudier; Jan Roigas; Silke Gillessen; Ulrika Harmenberg; Sandhya Srinivas; Sasja F Mulder; George Fountzilas; Christian Peschel; Per Flodgren; Edna Chow Maneval; Isan Chen; Nicholas J Vogelzang
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4068-75.
2009: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3312-8.
2009: M P Sablin; Sylvie Negrier; Alain Ravaud; Stéphane Oudard; Corinne Balleyguier; J Gautier; C Celier; J Medioni; Bernard Escudier
Sequential sorafenib and sunitinib for renal cell carcinoma.
The Journal of urology 2009;182(1):29-34; discussion 34.
2009: Karim Fizazi; Philippe Beuzeboc; Jean Lumbroso; Vincent Haddad; Christophe Massard; Marine Gross-Goupil; Mario Di Palma; Bernard Escudier; Christine Theodore; Yohann Loriot; Elodie Tournay; Jeannine Bouzy; Agnès Laplanche
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2429-35.
2009: Bernard Escudier; Marine Gross Goupil; Christophe Massard; Karim Fizazi
Sequential therapy in renal cell carcinoma.
Cancer 2009;115(10 Suppl):2321-6.
2009: Flavio L Heldwein; Bernard Escudier; Gordon Smyth; Carlos A V Souto; Guy Vallancien
Metastatic renal cell carcinoma management.
International braz j urol : official journal of the Brazilian Society of Urology 2009;35(3):256-70.
2009: Bernard Escudier; V Kataja
Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():81-2.
2009: Yohann Loriot; Christophe Massard; M Gross-Goupil; Mario Di Palma; Bernard Escudier; A Bossi; Karim Fizazi
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(4):703-8.
2009: Bernard Escudier; Cezary Szczylik; Thomas E Hutson; Tomasz Demkow; Michael Staehler; Frédéric Rolland; Sylvie Negrier; Nicole Laferriere; Urban J Scheuring; David Cella; Sonalee Shah; Ronald M Bukowski
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1280-9.
2009: Caroline Robert; Christine Mateus; Alain Spatz; Janine Wechsler; Bernard Escudier
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
Journal of the American Academy of Dermatology 2009;60(2):299-305.
2009: Sophie Viaud; Magali Terme; Caroline Flament; Julien Taieb; Fabrice André; Sophie Novault; Bernard Escudier; Caroline Robert; Sophie Caillat-Zucman; Thomas Tursz; Laurence Zitvogel; Nathalie Chaput
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.
PloS one 2009;4(3):e4942.
2008: M Bennani-Lahlou; Christine Mateus; Bernard Escudier; Christophe Massard; Jean-Charles Soria; Alain Spatz; Caroline Robert
[Eruptive nevi associated with sorafenib treatment].
Annales de dermatologie et de vénéréologie 2008;135(10):672-4.
2008: Bernard Escudier; Jan Cosaert; Pavel Pisa
Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.
Expert review of anticancer therapy 2008;8(10):1545-57.
2008: Bernard Escudier; Jan Cosaert; sangeeta jethwa
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.
Biologics : targets & therapy 2008;2(3):517-30.
2008: Bernard Escudier
Signaling inhibitors in metastatic renal cell carcinoma.
Cancer journal (Sudbury, Mass.) 2008;14(5):325-9.
2008: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet 2008;372(9637):449-56.
2008: Bernard Escudier; Marine Gross-Goupil
[Revolution in treatment of renal carcinoma: molecular rational and clinical approach].
Médecine sciences : M/S 2008;24(8-9):697-9.
2008: Bernard Escudier
Comments on the article "Targeted therapy in renal cell carcinoma" by J.-J. Patard et al.
World journal of urology 2008;26(4):409-10.
2008: Julien Autier; Bernard Escudier; Janine Wechsler; Alain Spatz; Caroline Robert
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Archives of dermatology 2008;144(7):886-92.
2008: R Thuret; Christophe Massard; M Gross-Goupil; Bernard Escudier; Mario Di Palma; A Bossi; Renaud De Crevoisier; A Chauchereau; Karim Fizazi
The postchemotherapy PSA surge syndrome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(7):1308-11.
2008: Emilie Viey; Claire Lucas; François Romagne; Bernard Escudier; Salem Chouaib; Anne Caignard
Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(3):313-23.
2008: Toni K Choueiri; Anne Plantade; Paul Elson; Sylvie Negrier; Alain Ravaud; Stéphane Oudard; Ming Zhou; Brian I Rini; Ronald M Bukowski; Bernard Escudier
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):127-31.
2007: Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Lancet 2007;370(9605):2103-11.
2007: Sylvie Negrier; David Perol; Alain Ravaud; Christine Chevreau; Jacques-Olivier Bay; Rémi Delva; Emmanuel Sevin; Armelle Caty; Bernard Escudier
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Cancer 2007;110(11):2468-77.
2007: Arnaud Mejean; Jean-Michel Correas; Bernard Escudier; Marc De Fromont; Hervé Lang; Jean-Alexandre Long; Yann Neuzillet; Jean-Jacques Patard; Thierry Piechaud
[Kidney tumors].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2007;17(6):1101-44.
2007: Bernard Escudier; Toni K Choueiri; Stéphane Oudard; Cezary Szczylik; Sylvie Négrier; Alain Ravaud; Christine Chevreau; Peter Venner; Patrick Champagne; Daniel Croteau; Eric Dupont; Claude Hariton; Ronald M Bukowski
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
The Journal of urology 2007;178(5):1901-5.
2007: Robert J Motzer; Gary R Hudes; Brendan D Curti; David F McDermott; Bernard Escudier; Sylvie Negrier; Brigitte Duclos; Laurence Moore; Timothy O'Toole; Joseph P Boni; Janice P Dutcher
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3958-64.
2007: Bernard Escudier
Sorafenib [corrected] in kidney cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 9():ix90-3.
2007: Sebastian Wittnebel; Sylvie Da Rocha; Julien Giron-Michel; Abdelali JALIL; Paule Opolon; Bernard Escudier; Pierre Validire; Krystel Khawam; Salem Chouaib; Bruno Azzarone; Anne Caignard
Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
Cancer research 2007;67(12):5594-9.
2007: Stéphane Oudard; Eugeniu Banu; Annick Vieillefond; Laure Fournier; Frank Priou; Jacques Medioni; Adela Banu; Brigitte Duclos; Frédéric Rolland; Bernard Escudier; Nina Arakelyan; Stéphane Culine
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
The Journal of urology 2007;177(5):1698-702.
2007: Bernard Escudier; Nathalie Lassau; Eric Angevin; Jean-Charles Soria; Linda Chami; Michele Lamuraglia; Eric Zafarana; Veronique Landreau; Brian Schwartz; Eric Brendel; Jean-Pierre Armand; Caroline Robert
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1801-9.
2007: Karim Fizazi; Luc Morat; Laurent Chauveinc; Dominique Prapotnich; Renaud De Crevoisier; Bernard Escudier; Xavier Cathelineau; François Rozet; G Vallancien; Laure Sabatier; Jean-Charles Soria
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):518-21.
2007: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Sorafenib in advanced clear-cell renal-cell carcinoma.
The New England journal of medicine 2007;356(2):125-34.
2007: Bernard Escudier
Advanced renal cell carcinoma: current and emerging management strategies.
Drugs 2007;67(9):1257-64.
2006: Michele Lamuraglia; Bernard Escudier; Linda Chami; Brian Schwartz; Jérome Leclère; Alain Roche; Nathalie Lassau
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
European journal of cancer (Oxford, England : 1990) 2006;42(15):2472-9.
2005: Nicolas van Baren; Marie-Claude Bonnet; Brigitte Dréno; Amir Khammari; Thierry Dorval; Sophie Piperno-Neumann; Danielle Liénard; Daniel Speiser; Marie Marchand; Vincent G Brichard; Bernard Escudier; Sylvie Négrier; Pierre-Yves Dietrich; Dominique Maraninchi; Susanne Osanto; Ralf G Meyer; Gerd Ritter; Philippe Moingeon; Jim Tartaglia; Pierre van der Bruggen; Pierre G Coulie; Thierry Boon
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(35):9008-21.
2005: Emilie Viey; Catherine Laplace; Bernard Escudier
Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
Expert review of anticancer therapy 2005;5(6):973-86.
2005: Wim H J Kruit; Heidi H van Ojik; Vincent G Brichard; Bernard Escudier; Thierry Dorval; Brigitte Dréno; Poulam Patel; Nicolas van Baren; Marie-Françoise Avril; Sophie Piperno; Amir Khammari; Marguerite Stas; Gerd Ritter; Bernard Lethé; Danièle Godelaine; Francis Brasseur; Yi Zhang; Pierre van der Bruggen; Thierry Boon; Alexander M M Eggermont; Marie Marchand
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
International journal of cancer. Journal international du cancer 2005;117(4):596-604.
2005: François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre-Emmanuel Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
The Journal of experimental medicine 2005;202(8):1075-85.
2005: Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
The lancet oncology 2005;6(7):491-500.
2005: Sylvie Negrier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; David Perol; Christine Lasset; Bernard Escudier
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
World journal of urology 2005;23(3):161-5.
2005: Sebastian Wittnebel; Abdelali JALIL; Jerome THIERY; S DaRocha; Emilie Viey; Bernard Escudier; Salem Chouaib; Anne Caignard
The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.
European cytokine network 2005;16(2):123-7.
2005: Emilie Viey; Gaëlle Fromont; Bernard Escudier; Yannis Morel; Sylvie Da Rocha; Salem Chouaib; Anne Caignard
Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(3):1338-47.
2004: Nathalie Lassau; Imad Chawi; Valérie Rouffiac; Sophie Bidault; Bernard Escudier; Jérome Leclère
[Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma].
Bulletin du cancer 2004;91(7-8):629-35.
2004: Sylvie Negrier; David Perol; Christine Menetrier-Caux; Bernard Escudier; Marc Pallardy; Alain Ravaud; Jean-Yves Douillard; Christine Chevreau; Christine Lasset; Jean-Yves Blay; Michel Pallardy
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2371-8.
2004: Asma Gati; Sylvie Da Rocha; Nadia Guerra; Bernard Escudier; Alessandro Moretta; Salem Chouaib; Eric Angevin; Anne Caignard
Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients.
International journal of cancer. Journal international du cancer 2004;109(3):393-401.
2004: Nathalie Chaput; Noël Emile Célestin Schartz; Fabrice André; Julien Taïeb; Sophie Novault; Pierre Bonnaventure; Nathalie Aubert; Jacky Bernard; François Lemonnier; Miriam Merad; Gosse J Adema; Malcolm Adams; Maria Ferrantini; Antoine F Carpentier; Bernard Escudier; Thomas Tursz; Eric Angevin; Laurence Zitvogel
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2137-46.
2004: Fabrice André; Nathalie Chaput; Noël Emile Célestin Schartz; Caroline Flament; Nathalie Aubert; Jacky Bernard; François Lemonnier; Graça Raposo; Bernard Escudier; Di-Hwei Hsu; Thomas Tursz; Sebastian Amigorena; Eric Angevin; Laurence Zitvogel
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2126-36.
2004: Fabrice Andre; Bernard Escudier; Eric Angevin; Thomas Tursz; Laurence Zitvogel
Exosomes for cancer immunotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv141-4.
2003: Patrick Saulnier; Michel Vidaud; Eric Gautier; Nelly Motté; Dominique Bellet; Bernard Escudier; Deborah Wilson; Antoine Yver
Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201).
Journal of virological methods 2003;114(1):55-64.
2003: Asma Gati; Nadia Guerra; Catherine Gaudin; Sylvie Da Rocha; Bernard Escudier; Yann Lécluse; Ali Bettaieb; Salem Chouaib; Anne Caignard
CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling.
Cancer research 2003;63(21):7475-82.
2003: Nathalie Chaput; Fabrice Andre; Noël Emile Célestin Schartz; Caroline Flament; Eric Angevin; Bernard Escudier; Laurence Zitvogel
[Exosomes and anti-tumour immunotherapy].
Bulletin du cancer 2003;90(8-9):695-8.
2003: Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean Pierre Droz; Dominique Mery-Mignard; Stéphane Culine; Bernard Escudier
A phase II study of irinotecan in patients with advanced renal cell carcinoma.
Cancer 2003;98(1):61-5.
2003: Frank Griscelli; Paule Opolon; Patrick Saulnier; Fathia Mami-Chouaib; E Gautier; Hamid Echchakir; Eric Angevin; T Le Chevalier; V Bataille; Patrick Squiban; Thomas Tursz; Bernard Escudier
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.
Gene therapy 2003;10(5):386-95.
2003: Dominique Prapotnich; Karim Fizazi; Bernard Escudier; Annick Mombet; Nathalie Cathala; Guy Vallancien
A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.
European urology 2003;43(3):233-39; discussion 239-40.
2003: Marie Marchand; Cornelis J A Punt; Steinar Aamdal; Bernard Escudier; Wim H J Kruit; U Keilholz; L Håkansson; Nicolas van Baren; Yves Humblet; P Mulders; M-F Avril; Alexander M M Eggermont; C Scheibenbogen; J Uiters; Jantien Wanders; M Delire; Thierry Boon; Gerrit Stoter
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
European journal of cancer (Oxford, England : 1990) 2003;39(1):70-7.
2002: Nadia Guerra; Frédérique Michel; Asma Gati; Catherine Gaudin; Zohar Mishal; Bernard Escudier; Oreste Acuto; Salem Chouaib; Anne Caignard
Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction.
Blood 2002;100(8):2874-81.
2002: Sylvie Negrier; Arnaud Mejean; Stéphane Oudard; Bernard Escudier
[Metastatic kidney cancer: new therapeutic approaches].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2002;12(4):703-8.
2002: Sylvie Négrier; Bernard Escudier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; D Pérol; Christine Lasset
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(9):1460-8.
2002: Bernard Escudier; Jean Pierre Droz; Frédéric Rolland; M J Terrier-Lacombe; G Gravis; Philippe Beuzeboc; B Chauvet; Christine Chevreau; Jean-Christophe Eymard; Thierry Lesimple; Yacine Merrouche; Stéphane Oudard; Frank Priou; C Guillemare; Sophie Gourgou; Stéphane Culine
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
The Journal of urology 2002;168(3):959-61.
2002: Gerald Batist; François Patenaude; Patrick Champagne; Daniel Croteau; Carey Levinton; Claude Hariton; Bernard Escudier; Eric Dupont
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1259-63.
2002: Fabrice Andre; Noël Emile Célestin Schartz; Mojgan Movassagh; Caroline Flament; Patricia Pautier; Philippe Morice; Christophe Pomel; Catherine Lhomme; Bernard Escudier; Thierry Le Chevalier; Thomas Tursz; Sebastian Amigorena; Graça Raposo; Eric Angevin; Laurence Zitvogel
Malignant effusions and immunogenic tumour-derived exosomes.
Lancet 2002;360(9329):295-305.
2002: Bernard Escudier; Nathalie Lassau; Dominique Couanet; Eric Angevin; F Mesrati; S Leborgne; A Garofano; Christophe Leboulaire; N Dupouy; Agnès Laplanche
Phase II trial of thalidomide in renal-cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1029-35.
2002: Bernard Escudier; Nathalie Lassau; S Leborgne; Eric Angevin; Agnès Laplanche
Thalidomide and venous thrombosis.
Annals of internal medicine 2002;136(9):711.
2002: Sylvie Negrier; Jean-Yves Douillard; Frédéric Gomez; Christine Lasset; Christine Chevreau; Bernard Escudier
[Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2002;12(2):213-8.
2002: Christoph Rochlitz; Brigitte Dreno; Peter Jantscheff; Franco Cavalli; Patrick Squiban; Bruce Acres; Martine Baudin; Bernard Escudier; Lucie Heinzerling; Rudolf Morant; Richard Herrmann; Pierre-Yves Dietrich; Reinhard Dummer
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
Cancer gene therapy 2002;9(3):289-95.
2001: G Gravis; Mireille Mousseau; Jean-Yves Douillard; Thierry Dorval; Michel Fabbro; Bernard Escudier; L Mignot; Patrice Viens
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial.
European cytokine network 2001;12(2):239-43.
2000: Sylvie Négrier; Armelle Caty; Thierry Lesimple; Jean-Yves Douillard; Bernard Escudier; Jean-François Rossi; Patrice Viens; F Gomez
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4009-15.
2000: Sylvie Négrier; Liliane Ollivier; D Di Stefano-Louineau; Bernard Escudier; Jacqueline Savary; Christine Lasset; Philippe Thiesse
[Reliability of the response rate in oncology: analysis of the causes for variation].
Bulletin du cancer 2000;87(12):927-34.
2000: Miriam Merad; Eric Angevin; J Wolfers; Caroline Flament; I Lorenzi; Frédéric Triebel; Bernard Escudier; Laurence Zitvogel
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(3):369-78.
2000: Nadia Guerra; M Guillard; Eric Angevin; Hamid Echchakir; Bernard Escudier; Alessandro Moretta; Salem Chouaib; Anne Caignard
Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas.
Blood 2000;95(9):2883-9.
2000: Sylvie Negrier; J Maral; M Drevon; J Vinke; Bernard Escudier; Thierry Philip
Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
The cancer journal from Scientific American 2000;6 Suppl 1():S93-8.
2000: Jean-Pierre Delord; Eric Raymond; M Chaouche; P Ruffie; Michel Ducreux; Sandrine Faivre; Valérie Boige; Thierry Le Chevalier; Olivier Rixe; Eric Baudin; Patricia Pautier; J M Rodier; N Chouaki; Bernard Escudier; Louis Kayitalire; Jean-Pierre Armand
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(1):73-9.
2000: Nacilla Haicheur; Bernard Escudier; Thierry Dorval; Sylvie Negrier; P H De Mulder; J M Dupuy; D Novick; T Guillot; Stanley Wolf; P Pouillart; Wolf H Fridman; Eric Tartour
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients.
Clinical and experimental immunology 2000;119(1):28-37.
1999: Bernard Escudier; Christine Chevreau; Christine Lasset; Jean-Yves Douillard; Alain Ravaud; M Fabbro; Armelle Caty; Jean-François Rossi; Patrice Viens; Jean-Pierre Bergerat; Jacqueline Savary; Sylvie Négrier
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2039-43.
1999: Eric Angevin; L Glukhova; C Pavon; A Chassevent; Marie-José Terrier-Lacombe; AF Goguel; J Bougaran; Patrice Ardouin; Bernard Court; JL Perrin; G Vallancien; Frédéric Triebel; Bernard Escudier
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis.
Laboratory investigation; a journal of technical methods and pathology 1999;79(7):879-88.
1999: A Le Cesne; G Vassal; Françoise Farace; Marc Spielmann; T Le Chevalier; Eric Angevin; Dominique Valteau-Couanet; Karim Fizazi; I Cojean; A Llombard; Thomas Tursz; Bernard Escudier
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(3):268-77.
1999: Thierry Dorval; Sylvie Négrier; Christine Chevreau; M F Avril; D Baume; Didier Cupissol; R Oskam; R de Peuter; J Vinke; A Herrera; Bernard Escudier
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Cancer 1999;85(5):1060-6.
1998: Stéphane Culine; M Bekradda; A Kramar; Annie Rey; Bernard Escudier; Jean Pierre Droz
Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.
Cancer 1998;83(12):2548-53.
1998: Jean-Pierre Delord; J Alexandre; C Chevreau; Bernard Escudier
[Cancer of the kidney in the adult].
Bulletin du cancer 1998;(1 Suppl):4-15.
1998: Alain Ravaud; Bruno Audhuy; F Gomez; Bernard Escudier; Thierry Lesimple; Christine Chevreau; Jean-Yves Douillard; Armelle Caty; Lionel Geoffrois; J M Ferrero; C Linassier; M Drevon; Sylvie Négrier
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2728-32.
1998: L Glukhova; AF Goguel; I Chudoba; Eric Angevin; C Pavon; Marie-José Terrier-Lacombe; Mounira Meddeb; Bernard Escudier; Alain BERNHEIM
Overrepresentation of 7q31 and 17q in renal cell carcinomas.
Genes, chromosomes & cancer 1998;22(3):171-8.
1998: Sylvie Negrier; Bernard Escudier; Christine Lasset; Jean-Yves Douillard; Jacqueline Savary; Christine Chevreau; Alain Ravaud; A Mercatello; Jean Peny; Mireille Mousseau; T Philip; T Tursz
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
The New England journal of medicine 1998;338(18):1272-8.
1998: M Guiguet; François Blot; Bernard Escudier; Sami Antoun; B Leclercq; Gérard Nitenberg
Severity-of-illness scores for neutropenic cancer patients in an intensive care unit: Which is the best predictor? Do multiple assessment times improve the predictive value?
Critical care medicine 1998;26(3):488-93.
1998: Bernard Escudier; Alain Ravaud; D Berton; Christine Chevreau; J Y Douillard; P Y Dietrich
Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(1):62-4.
1997: Philippe Thiesse; Liliane Ollivier; D Di Stefano-Louineau; Sylvie Négrier; Jacqueline Savary; K Pignard; Christine Lasset; Bernard Escudier
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(12):3507-14.
1997: Françoise Farace; Eric Angevin; Isabelle Poullion; C Leboullaire; G Ferir; D Elias; Bernard Escudier; Frédéric Triebel
T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines.
International journal of cancer. Journal international du cancer 1997;71(6):972-7.
1997: François Blot; M Guiguet; Gérard Nitenberg; B Leclercq; Bertrand Gachot; Bernard Escudier
Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1031-7.
1996: Anne Caignard; M Guillard; Catherine Gaudin; Bernard Escudier; Frédéric Triebel; Pierre-Yves Dietrich
In situ demonstration of renal-cell-carcinoma-specific T-cell clones.
International journal of cancer. Journal international du cancer 1996;66(4):564-70.
1996: Eric Tartour; Jean-Yves Blay; Thierry Dorval; Bernard Escudier; Véronique Mosseri; Jean-Yves Douillard; Laurent Deneux; I Gorin; Sylvie Negrier; Claire Mathiot; Pierre Pouillart; Wolf H Fridman
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1697-703.
1996: D Valteau; V Scott; G Carcelain; Olivier Hartmann; Bernard Escudier; T Hercend; Frédéric Triebel
T-cell receptor repertoire in neuroblastoma patients.
Cancer research 1996;56(2):362-9.
1996: Salem Chouaib; Bernard Escudier; Jihed Chehimi
Cellular and molecular immunology of an important regulatory cytokine. New York 9-12, November 1995.
European cytokine network 1996;7(1):79-81.
1995: Bernard Escudier
[Immunotherapy in metastatic cancer of the kidney].
Presse médicale (Paris, France : 1983) 1995;24(32):1504-6.
1995: Eric Angevin; Dominique Valteau-Couanet; Françoise Farace; Pierre-Yves Dietrich; A Lecesne; Frédéric Triebel; Bernard Escudier
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):188-95.
1995: Dominique Elias; Françoise Farace; Frédéric Triebel; J M Hattchouel; J P Pignon; A Lecesne; Philippe Rougier; Philippe Lasser; P Duvillard; Bernard Escudier
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Journal of the American College of Surgeons 1995;181(4):303-10.
1995: Françoise Farace; Eric Angevin; Pierre-Yves Dietrich; C Leboullaire; J Vanderplancke; Bernard Escudier; Frédéric Triebel
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo.
International journal of cancer. Journal international du cancer 1995;62(5):523-8.
1995: Bernard Escudier; J L Lethiec; Eric Angevin; Antoine Andremont; M F Cosset-Delaigue; Sami Antoun; B Leclercq; Gérard Nitenberg
Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(5):297-300.
1995: François Blot; M Guiguet; Sami Antoun; B Leclercq; Gérard Nitenberg; Bernard Escudier
Early tracheotomy in neutropenic, mechanically ventilated patients: rationale and results of a pilot study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(5):291-6.
1995: M Michel; F Vincent; R Sigal; G Damaj; T A Bensousan; B Leclercq; Bernard Escudier
Cerebral vasculitis after interleukin-2 therapy for renal cell carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(2):124-6.
1995: François Blot; Gérard Nitenberg; M Guiguet; M Casetta; Sami Antoun; José-Luis Pico; B Leclercq; Bernard Escudier
Safety of tracheotomy in neutropenic patients: a retrospective study of 26 consecutive cases.
Intensive care medicine 1995;21(8):687-90.
1995: L Mounedji-Boudiaf; Philippe Rougier; Stéphane Culine; Thierry de Baere; Philippe Lasser; Bernard Escudier; Michel Ducreux; E Kaloustian; Jean Pierre Droz; A Roche
[Treatment of metastatic malignant insulinomas. 2 cases].
Presse médicale (Paris, France : 1983) 1995;24(19):894-6.
1995: Bernard Escudier; Françoise Farace; Christine Théodore; Eric Angevin; Bernard Court; D Couanet; Pierre-Yves Dietrich; Stéphane Culine; Marc Pallardy; T Hercend
[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute].
Bulletin du cancer 1995;82(4):296-302.
1995: Catherine Gaudin; Pierre-Yves Dietrich; S Robache; M Guillard; Bernard Escudier; M J Lacombe; A Kumar; Frédéric Triebel; Anne Caignard
In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
Cancer research 1995;55(3):685-90.
1994: Françoise Farace; Eric Angevin; J Vanderplancke; Bernard Escudier; Frédéric Triebel
The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration.
International journal of cancer. Journal international du cancer 1994;59(6):752-5.
1994: Bernard Escudier; Alain Ravaud; M Fabbro; Jean-Yves Douillard; Sylvie Négrier; Christine Chevreau; L Mignot; D Baume; Thierry Dorval; F Vignal
High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(4):306-12.
1994: A Moran-Ribon; Jean Pierre Droz; Joseph Kattan; B Leclercq; Marwan Ghosn; D Couanet; M Ostronoff; Stéphane Culine; B Misset; Bernard Escudier
Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(4):253-8.
1994: E Savelieva; Françoise Farace; Eric Angevin; D Elias; Bernard Escudier; P Duvillard; T Hercend; Frédéric Triebel
T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(1):66-76.
1994: Françoise Farace; Marc Pallardy; Eric Angevin; T Hercend; Bernard Escudier; Frédéric Triebel
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring.
International journal of cancer. Journal international du cancer 1994;57(6):814-21.
1994: Bernard Escudier; Françoise Farace; Eric Angevin; F Charpentier; Gérard Nitenberg; Frédéric Triebel; T Hercend
Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1078-83.
1993: Françoise Farace; Eric Angevin; Bernard Escudier; Anne Caignard; Pierre-Yves Dietrich; C Genevee; T Hercend; Frédéric Triebel
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma.
International journal of cancer. Journal international du cancer 1993;54(5):741-7.
1993: Pierre-Yves Dietrich; Françoise Farace; Anne Caignard; Bernard Escudier; Frédéric Triebel
[Cancer immunotherapy: immunologic bases, reality and hopes].
Bulletin du cancer 1993;80(7):584-600.
1993: Eric Angevin; Françoise Farace; C Genevée; Michel Henry-Amar; Anne Caignard; Pierre-Yves Dietrich; Bernard Escudier; T Hercend; Frédéric Triebel
Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients.
International journal of cancer. Journal international du cancer 1993;54(1):60-7.
1993: F Triebel; Bernard Escudier
[Cytokines and solid tumors].
La Revue du praticien 1993;43(5):580-5.
1993: Bernard Escudier; Françoise Farace; Eric Angevin; Frédéric Triebel; Sami Antoun; B Leclercq; M Brandely; A Aboudaram; Gérard Nitenberg; T Hercend
Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 1993;29A(5):724-8.
1993: Dominique Elias; Philippe Lasser; J M Hatchouel; Bernard Escudier; M Spielmann; Theodore Girinsky; J Kac
[A multivariate prospective study of prognostic factors in 200 operated epidermoid cancers of the esophagus. Definition of patients for whom surgical resection was of benefit].
Gastroentérologie clinique et biologique 1993;17(1):17-25.
1992: Dominique Elias; Philippe Lasser; H Mankarios; P A Cabanes; Bernard Escudier; J Kac; Philippe Rougier
Esophageal squamous cell carcinoma: the specific limited place of surgery defined by a prospective multivariate study of prognostic factors after surgical approach.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1992;18(6):563-71.
1992: Jean Pierre Droz; Andrew Kramar; Pierre Wibault; J J Perrin; Alain Roche; Bernard Escudier; Gilles Missenard; Bernard Court
[Therapeutic strategy in metastatic renal cancer].
La Revue du praticien 1992;42(10):1253-7.
1992: Françoise Farace; A M Le Ridant; Bernard Escudier; T Hercend; F Triebel
Studies on NK cell purification by negative selection in human peripheral blood.
Biotherapy (Dordrecht, Netherlands) 1992;5(1):11-20.
1991: B Misset; Bernard Escudier; D Rivara; B Leclercq; G Nitenberg
Heat and moisture exchanger vs heated humidifier during long-term mechanical ventilation. A prospective randomized study.
Chest 1991;100(1):160-3.
1991: B Misset; Denis Glotz; Bernard Escudier; D Nochy; J Bosq; Erard Gilles; B Leclercq; G Nitenberg
Wegener's granulomatosis presenting as diffuse pulmonary hemorrhage.
Intensive care medicine 1991;17(2):118-20.
1990: T Hercend; Françoise Farace; D Baume; F Charpentier; J P Droz; Frédéric Triebel; Bernard Escudier
Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Journal of biological response modifiers 1990;9(6):546-55.
1990: P Lang; I Vitté-Mony; Françoise Farace; Rodica Stancou; Frédéric Triebel; Bernard Escudier; T Hercend; Jacques Bertoglio
In vivo activation of LAK cells during systemic IL-2 therapy.
European cytokine network 1990;1(3):185-8.
1990: B Misset; Bernard Escudier; B Leclercq; D Rivara; P Rougier; G Nitenberg
Acute myocardiotoxicity during 5-fluorouracil therapy.
Intensive care medicine 1990;16(3):210-1.
1989: Dominique Elias; Marc Spielmann; J Kac; Theodore Girinsky; T Guillot; L Pendola; F Bertin; Bernard Escudier; Philippe Rougier; Philippe Lasser
[Epidermoid cancer of the esophagus: is the combination of chemotherapy then surgery beneficial?].
Bulletin du cancer 1989;76(7):717-27.